Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $1.88
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Apr 29, 26 |
Daily · Wilder smoothing
| BTIG |
| maintain |
| Buy |
| Buy |
| Mar 17, 26 | Wedbush | maintain | Outperform | Outperform |
| Jan 16, 26 | Piper Sandler | maintain | Overweight | Overweight |
| Dec 4, 25 | Guggenheim | downgrade | Buy | Neutral |
| Aug 11, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Mar 18, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Mar 7, 25 | Stifel | maintain | Buy | Buy |
| Nov 6, 24 | HC Wainwright & Co. | maintain | Buy | Buy |
| Oct 9, 24 | HC Wainwright & Co. | maintain | Buy | Buy |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 48.89 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 76.54 | Oscillator | Neutral |
| Williams %R (14) | -48.15 | Oscillator | Neutral |
| MACD (12, 26, 9) | 0.00 (Hist 0.03) | Oscillator | Strong Buy |
| Average Directional Index (14) | 20.16 (+DI 24.7 / -DI 24.2) | Trend | Buy |
| EMA 20 | 1.89 | MA | Sell |
| SMA 20 | 1.86 | MA | Buy |
| EMA 50 | 1.93 | MA | Sell |
| SMA 50 | 1.98 | MA | Strong Sell |
| SMA 200 | 2.22 | MA | Strong Sell |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 18, 26 | Behbahani Ali | director | A-Award | 7,707 @ $1.93 | $14.87K |
| Sep 18, 26 | Raman Prakash | director | A-Award | 6,801 @ $1.93 | $13.13K |
| Jun 26, 26 | Behbahani Ali | director | A-Award | 40,000 @ $1.71 | $68.40K |
| Jun 26, 26 | Kulkarni Samarth | director | A-Award | 40,000 @ $1.71 | $68.40K |
| Jun 26, 26 | Menzel Garry E | director | A-Award | 40,000 @ $1.71 | $68.40K |
| Jun 26, 26 | Raman Prakash | director | A-Award | 40,000 @ $1.71 | $68.40K |
| Jun 26, 26 | Dhingra Kapil | director | A-Award | 40,000 @ $1.71 | $68.40K |
| Jun 26, 26 | Campbell Shannon | director | A-Award | 40,000 @ $1.71 | $68.40K |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Sep 21, 2026 | 2026-09-21 17:45:30 | View |
| 4 | Sep 21, 2026 | 2026-09-21 17:30:27 | View |
| 10-Q | Aug 5, 2026 | 2026-08-05 16:04:38 | View |
| 8-K | Aug 5, 2026 | 2026-08-05 16:02:17 | View |
| SC 13G | Jul 27, 2026 | 2026-07-27 16:25:25 | View |
| SC 13G/A | Jul 8, 2026 | 2026-07-08 11:30:22 | View |
| 4 | Jun 29, 2026 | 2026-06-29 16:40:15 | View |
| 4 | Jun 29, 2026 | 2026-06-29 16:37:58 | View |
| 4 | Jun 29, 2026 | 2026-06-29 16:37:15 | View |
| 4 | Jun 29, 2026 | 2026-06-29 16:36:15 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | BDTX | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -2.5x | 0.2x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -3.1x | EPS est. -0.62 | Elevated |
| Price / Book | 1.1x | 1.1x | In line |
| Price / Sales | — | 0.4x | Discount |
| EV / EBITDA | -2.6x | 0.3x | Discount |
| Return on equity | -38.8% | — | Weak |
| Gross margin | 0.0% | 19.9% | Below hist. |
| Debt / Equity | 0.18 | 0.21 | Conservative |
| Piotroski / Altman Z | 1/9 | Z -3.07 | Distress |
Discounted cash flow model
Stock news · updated daily
Black Diamond Therapeutics (NASDAQ: BDTX - Get Free Report) and Absci (NASDAQ: ABSI - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership. Insider and Institutional Ownership 95.5% of Black
Pliant Therapeutics (NASDAQ: PLRX - Get Free Report) and Black Diamond Therapeutics (NASDAQ: BDTX - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, valuation and analyst recommendations. Profitability This table compares Pliant Therapeutics
CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, including silevertinib, a potential best-in-class brain-penetrant epidermal growth factor receptor (EGFR) inhibitor, today announced that its Chief Scientific Officer, Elizabeth Buck, Ph.D.
CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, including silevertinib, a potential best-in-class brain-penetrant epidermal growth factor receptor (EGFR) inhibitor, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 5, 2026 | -0.20 | -0.17 | Beat 13.0% | — |
| May 7, 2026 | -0.18 | -0.16 | Beat 11.1% | — |
| Mar 16, 2026 | -0.18 | -0.26 | Miss -44.4% | — |
| Nov 6, 2025 | -0.22 | -0.15 | Beat 31.8% | — |
| Aug 7, 2025 | -0.25 | -0.19 | Beat 24.0% | — |
| May 12, 2025 | 0.02 | 0.98 | Beat 4800.0% | $70.00M |
FY2025 · 10-K disclosure